IDH mutations are promising targets for acute myeloid leukemia

被引：0
|
作者：
Ogawara, Yoko [1 ]
Matsunaga, Hironori [2 ]
Seki, Takahiko [2 ]
Machida, Yukino [1 ]
Araki, Kazushi [2 ]
Kitabayashi, Issay [1 ]
机构：
[1] Natl Canc Ctr, Res Inst, Div Hematol Malignancy, Tokyo 104, Japan
[2] Daiichi Sankyo Co Ltd, R&D Div, Tokyo, Japan
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-LB-252
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-252
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia
    Lu, Jingtao
    Chen, Meiyu
    Hua, Haiying
    Qin, Wei
    Zhang, Ri
    Lu, Xuzhang
    Chao, Hongying
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (06) : 1483 - 1490
  • [42] Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis
    Feng, Jian-Hua
    Guo, Xiao-Ping
    Chen, Yuan-Yuan
    Wang, Zhu-Jun
    Cheng, Yu-Ping
    Tang, Yong-Min
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2012, 2 (04): : 254 - 264
  • [43] Deep Sequencing of Acute Myeloid Leukemia Reveals Driver Mutations and New Targets
    Brower, Vicki
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (02):
  • [44] Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia
    Aziz, Habsah
    Ping, Chow Y.
    Alias, Hamidah
    Ab Mutalib, Nurul-Syakima
    Jamal, Rahman
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [45] IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring? (vol 61, pg 34, 2018)
    Petrova, Lucie
    Vrbacky, Filip
    Lanska, Miriam
    Zavrelova, Alzbeta
    Zak, Pavel
    Hrochova, Katerina
    CLINICAL BIOCHEMISTRY, 2019, 63 : 161 - 161
  • [46] IDH Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Stein, Eytan M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 556 - 558
  • [47] IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the acute leukemia french association
    Debarri, Houria
    Lebon, Delphine
    Roumier, Christophe
    Cheok, Meyling
    Marceau-Renaut, Alice
    Nibourel, Olivier
    Geffroy, Sandrine
    Helevaut, Nathalie
    Rousselot, Philippe
    Gruson, Berengere
    Gardin, Claude
    Chretien, Marie-Lorraine
    Sebda, Sheherazade
    Figeac, Martin
    Berthon, Celine
    Quesnel, Bruno
    Boissel, Nicolas
    Castaigne, Sylvie
    Dombret, Herve
    Renneville, Aline
    Preudhomme, Claude
    ONCOTARGET, 2015, 6 (39) : 42345 - 42353
  • [48] IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
    Cerchione, Claudio
    Romano, Alessandra
    Daver, Naval
    DiNardo, Courtney
    Jabbour, Elias Joseph
    Konopleva, Marina
    Ravandi-Kashani, Farhad
    Kadia, Tapan
    Martelli, Maria Paola
    Isidori, Alessandro
    Martinelli, Giovanni
    Kantarjian, Hagop
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [49] IDH1 and IDH2 mutations in pediatric acute leukemia
    Andersson, A. K.
    Miller, D. W.
    Lynch, J. A.
    Lemoff, A. S.
    Cai, Z.
    Pounds, S. B.
    Radtke, I.
    Yan, B.
    Schuetz, J. D.
    Rubnitz, J. E.
    Ribeiro, R. C.
    Raimondi, S. C.
    Zhang, J.
    Mullighan, C. G.
    Shurtleff, S. A.
    Schulman, B. A.
    Downing, J. R.
    LEUKEMIA, 2011, 25 (10) : 1570 - 1577
  • [50] Origin of Mutations in Acute Myeloid Leukemia
    Welch, John S.
    ANNALS OF HEMATOLOGY, 2017, 96 : S42 - S43
12345